Norden Group LLC Sells 5,086 Shares of Zoetis Inc. $ZTS

Norden Group LLC decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 26.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,066 shares of the company’s stock after selling 5,086 shares during the quarter. Norden Group LLC’s holdings in Zoetis were worth $1,770,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Halbert Hargrove Global Advisors LLC lifted its position in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares in the last quarter. Global Wealth Strategies & Associates acquired a new position in shares of Zoetis during the 4th quarter worth about $25,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Zoetis in the 3rd quarter valued at about $31,000. Holos Integrated Wealth LLC bought a new position in shares of Zoetis in the 4th quarter valued at about $32,000. Finally, Financial Consulate Inc. acquired a new stake in shares of Zoetis in the third quarter valued at about $39,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS opened at $116.62 on Friday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The business has a fifty day simple moving average of $123.62 and a 200 day simple moving average of $129.58. Zoetis Inc. has a 1 year low of $113.30 and a 1 year high of $172.23. The company has a market capitalization of $49.23 billion, a PE ratio of 19.37, a price-to-earnings-growth ratio of 1.78 and a beta of 0.95.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter last year, the business earned $1.40 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ZTS. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Bank of America upped their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. HSBC set a $140.00 price objective on Zoetis in a report on Wednesday, December 10th. Finally, The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Six analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.